A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...
Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...
A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the ...
A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...
Which genes are required for turning embryonic stem cells into brain cells, and what happens when this process goes wrong? In ...
By editing thousands of genes in mouse stem cells, the scientists identified a list of over 300 that are crucial for neural differentiation.
A sweeping genetic screen reveals how the brain is built and exposes a hidden gene behind a newly discovered childhood brain ...
Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...
Zacks Investment Research on MSN
Here is what to know beyond why CRISPR Therapeutics AG (CRSP) is a trending stock
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) laps the stock market: Here's why
In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.58% at $55.16. This change outpaced the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 1.23%, while the tech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results